Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0043 (IL-17A/IL-36R bispecific antibody) in moderate to severe acne vulgaris
ChiCTR2600120206Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in acne vulgaris comparing HB0043 continuous treatment arm with Placebo then HB0043 arm (2 arms). Primary endpoints: Count of inflammatory lesions and Overall Investigator Assessment (IGA) score. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HB0043
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2600120206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120206.